The increasing need for Closed System Drug Transfer Devices (CSTDs) is closely connected to the growth of cancer treatment services and the rising popularity of healthcare at home. These two factors are changing how healthcare works by emphasizing the crucial importance of safely handling and giving medications, especially those that can be harmful. The expansion of cancer services, driven by improvements in diagnosing and treating cancer, has led to more chemotherapy and related treatments. Places like outpatient cancer clinics and chemotherapy infusion centers are at the forefront of this growth, providing specialized care to cancer patients. According to the World Health Organization (WHO), cancer was the main cause of almost 10 million deaths in 2020, or about one in every six deaths. CSTDs are now essential in these places to ensure the safe preparation and giving of chemotherapy drugs, many of which are potent and dangerous. It's important to protect healthcare workers from potential exposure to these toxic substances, making the use of CSTDs a standard practice.
At the same time, the increase in home healthcare services has brought in a new way of caring for patients. Patients now get complex medical treatments, like chemotherapy, in the comfort of their homes. This change is not only convenient but has been sped up by the emphasis on reducing hospital visits due to the COVID-19 pandemic. CSTDs are crucial in home healthcare, where trained caregivers and even patients themselves give treatments. They allow the safe transfer of medications while lowering the risk of exposing family members and others in the home.
Also, this patient-centered approach fits with the main goal of improving the patient's experience and quality of care. Regulatory agencies, such as the U.S. FDA, recognize the need to ensure the safe handling of dangerous drugs in all healthcare settings, whether it's in a clinic or a patient's home. So, using CSTDs is required to meet regulatory standards, making them more common in both cancer services and home healthcare. Alongside this, competition in the market and a commitment to innovation in healthcare have led to improvements in CSTD technology. Manufacturers and suppliers are always working to meet the changing needs of healthcare providers, resulting in more advanced and user-friendly CSTDs. This competition makes these devices more appealing to healthcare facilities and home healthcare agencies as they look for top-notch solutions to ensure the safe administration of dangerous drugs.
Report Attribute/Metric | Details |
---|---|
Market Opportunities | Increased use of CSTDs in additional therapeutic areas |
Market Dynamics | Increasing the usage of CSTDs to counteract the negative effects of cytotoxic and antineoplastic medicines |
Closed System Drug Transfer Device (CSTD) Market size was valued at USD 0.85 billion in 2023. The Closed System Drug Transfer Device (CSTD) Market industry is projected to grow from USD 0.99 Billion in 2024 to USD 3.63 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.51% during the forecast period (2024 - 2032). The increasing use of hazardous drugs, oncology services, and home healthcare are increasing the demand for CSTDs, and stringent regulatory requirements within the healthcare industry are driving market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The escalating utilization of hazardous drugs within the healthcare sector stands as a compelling driver significantly shaping the global healthcare landscape. According to the Centers for Disease Control and Prevention, generally, about 8 million US healthcare personnel, including pharmacy and nursing staff, physicians, operating room workers, environmental services workers, workers in research laboratories, veterinary care workers, and shipping and receiving personnel, are potentially exposed to hazardous drugs.
Furthermore, the stringent regulatory landscape set forth by healthcare authorities, such as the U.S. Food and Drug Administration (FDA), has mandated the obligatory use of CSTDs during the intricate processes of hazardous drug preparation and administration. This regulatory framework underscores the critical role that CSTDs play in minimizing exposure risks, reinforcing their market presence as a non-negotiable component of modern healthcare practice. Moreover, this heightened awareness of safety protocols, coupled with the ever-expanding prevalence of chronic diseases, further accelerates the integration of CSTDs into the standard operating procedures of healthcare facilities worldwide.
The Closed System Drug Transfer Device (CSTD) Market segmentation, based on type, includes barrier type and filtration type. The barrier type segment held the majority share in 2022 in the Closed System Drug Transfer Device (CSTD) Market revenue. This is due to the growing geriatric population and rising awareness of CSTD devices. Moreover, the barrier-type devices block the accidental release of drugs into the environment and prevent the contamination caused due to the impurities in the outer environment.
CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET SIZE, BY TYPE, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Closed System Drug Transfer Device (CSTD) Market segmentation is based on closing mechanism that include push to turn system, color-to-color alignment system, leur lock systems, and others. The push to turn system segment has dominated the market in 2022 and leur lock systems segment is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is attributed to the increasing hospital admissions and expanding number of surgical procedures. Furthermore, the increasing number of cancer incidences globally and the need for such devices to reduce the risk associated with handling hazardous drugs is propelling the market growth for this segment.
March 2021: The U.S. Food and Drug Administration has approved Yukon Medical's (US) Arisure closed system transfer device (CSTD) under the ONB product classification.
The Closed System Drug Transfer Device (CSTD) Market segmentation is based on component that include vial access devices, syringe safety devices, bag/infusion set devices, and others. The vial access devices segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is attributed to the increasing prevalence of cancer and ease of use. Additionally, vial access devices are available with different properties such as needle-free that automatically equalizes vial pressure by reducing aerosols, prevents vaporization and leakage of drugs, and releases the desired volume of drugs from the device.
The Closed System Drug Transfer Device (CSTD) Market segmentation is based on technology that includes compartmentalize devices, diaphragm-based devices, and air filtration devices. The diaphragm-based devices segment has dominated the market in 2022 and compartmentalize devices is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is attributed to growing technological advancement and growing awareness about the availability of products. Additionally, diaphragm-based devices are employed extensively during pressure equalization. The technique prevents the spread of dangerous vapors and protects against harmful exposure.
The Closed System Drug Transfer Device (CSTD) Market segmentation is based on end user that includes hospitals & clinics, specialty centers, and others. The hospitals & clinics segment has dominated the market in 2022 and the specialty centers segment is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the high adoption of CSTD systems is due to the high purchasing power of big hospitals and growing healthcare infrastructure, and high purchasing power, and the growing awareness and adoption of CSTD devices for the delivery of many diseases as well as the increasing number of patients suffering from chronic diseases.
March 2022: Simplivia Healthcare, Ltd. (Israel) launched Chemfort, a closed-system drug transfer device that reduces the risk of exposure for healthcare professionals. This air-cleaning technology has been qualified as the most efficacious and user-friendly.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America closed system drug transfer device (CSTD) market accounted for the largest market share in 2022. This is due to the increasing prevalence of cancer cases and the strong research and development infrastructure in the North American region. For instance, In the United States in 2020, there were 1,603,844 new cancer cases reported and 602,347 cancer deaths. There were 403 new cancer cases reported for every 100,000 people, and 144 people died from cancer. Moreover, the presence of major market players, high awareness about CSTD products among end users, and recent technological advancements in the region are likely to enhance the growth of the CSTD market in North America.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 3: CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET SIZE, BY REGION 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe closed system drug transfer device (CSTD) market accounts for the second-largest market share due to the highly developed healthcare industry, prominent research, and development infrastructure, and accessibility of CSTD products in the region. Furthermore, Germany closed system drug transfer device (CSTD) market was attributed to hold the largest market share, and France closed system drug transfer device (CSTD) market is expected to fastest-growing market in the European region.
The Asia-Pacific closed system drug transfer device (CSTD) market is expected to grow at a significant share from 2024 to 2032. This is due to the increasing number of new vendors involved in the drug-device system, as there are many niche market players who are trying to leverage the market share. Moreover, China closed system drug transfer device (CSTD) market is expected to hold the largest market share, and India closed system drug transfer device (CSTD) market is expected fastest-growing market in the Asia-Pacific region.
Furthermore, in India, one in every nine people will develop cancer during their lifetime. Lung and breast cancers were the most common cancer sites in men and women, respectively. Many patients suffering from cancer and in need of delivery are anticipated to increase the lucrativeness of the region in the closed system drug transfer device (CSTD) market.
The Rest of the World is segmented into the Middle East, Africa, and Latin America. The closed system drug transfer device (CSTD) market in the above-mentioned regions is likely to witness growth due to technological advancement in the delivery of effective healthcare services and growing healthcare costs. Moreover, the increasing burden of cancer in Africa also influences the market.
Closed System Drug Transfer Device (CSTD) Key Market Players & Competitive Insights
The Closed System Drug Transfer Device (CSTD) Market is characterized by the presence of many global, regional, and local vendors. Developments in the healthcare industry and growing research and development make the closed system drug transfer device (CSTD) market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Becton, Dickinson and Company (US), B. Braun SE (Germany), Epic Medical (Singapore), and Simplivia Healthcare, Ltd. (Israel) dominate the Closed System Drug Transfer Device (CSTD) Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global closed system drug transfer device (CSTD) industry to benefit clients and expand the closed system drug transfer device (CSTD) market sector is to manufacture locally to reduce operating costs.
B.Braun (Germany) is a healthcare supplier and manufacturer that offers its products to hospitals, surgical units, private practices (medical care and doctors' offices), and extracorporeal blood treatments. It offers products in the following categories: clinical nutrition, urinary care, infection prevention, infusion therapy, diabetes care, neurosurgery, extracorporeal blood treatment, intravenous (IV) drugs, orthopedics, spine care, and wound care. The company offers approximately 5,000 products within the above-mentioned product category. Geographically, it operates in 64 countries in the region, including the Americas, Europe, Asia-Pacific, and the Middle East & Africa. For instance, in December 2021, B. Braun Medical Inc. (US), a subsidiary of B. Braun SE, launched OnGuard 2 in the US with upgraded materials and enhanced features to improve its usability. Moreover, OnGuard is designed to make OnGuard 2 easy to operate and adopt in healthcare practices.
Also, Simplivia (Israel) is a worldwide leader in the design, manufacturing, and delivery of drug delivery solutions. It is involved in advancing medical solutions for drug delivery to ensure the safety of medical professionals, such as nurses, pharmacists, and veterinarians. It operates in more than 33 countries across the region, namely the Americas, Europe, Asia-Pacific, and the Middle East & Africa. It offers a broad and innovative product pipeline that is Food and Drug Administration (US) and CE-approved. Furthermore, it sells its products, which are the highest International Organization for Standardization (ISO) across the globe. It has a presence in regions namely the Americas, Europe, Asia-Pacific, and the Middle East.
Key Companies in the Closed System Drug Transfer Device (CSTD) Market include
Closed System Drug Transfer Device (CSTD) Industry Developments
October 2022: Equashield (US) collaborated with Nordic Capital (US). Through this collaboration, Nordic Capital will assist Equashield in achieving its strategic goal of becoming the world leader in compounding technologies as well as accelerating its growth aspirations.
April 2019: Equashield (US) and Leaf Medical LTD (UK) have expanded the partnership to offer their manual and automatic Closed System Transfer Device (CSTD) solutions for the safe formulation and administration of hazardous medications.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)